Accelerant Holdings and Thoma Bravo signed a definitive merger agreement on Thursday. All cash, $20.25 a share for Class A and Class B stockholders, an enterprise value of more than $4 billion. The press release leads with the number that sells: a 49% premium to Accelerant’s closing price the day before.
Here is the number that doesn’t appear in the release. Accelerant priced its upsized initial public offering at $21.00 a share and started trading on the NYSE on July 24, 2025, raising roughly $724 million above a marketed range of $18 to $20. The buyout price is 3.6% below that. A specialty-insurance risk exchange spent thirteen months as a public company, and the exit — struck at a headline premium large enough to make the wires — still hands IPO buyers a loss.
Both facts are true simultaneously because the stock had fallen roughly 35% from the IPO price to about $13.59 before the bid landed. Premiums are measured from where a stock is, not from where investors bought it. In a year of broken 2025 listings, that distinction is doing a lot of work.
Our take: The 49% is not a valuation signal. Entities affiliated with Altamont Capital Partners, holding approximately 82% of outstanding voting rights, have already agreed to vote for the deal. There is no realistic contest, no auction dynamic, no interloper risk. What Thoma Bravo bought was a controlled company at a price the controller was willing to accept — and the controller’s cost basis is not $21. Minority holders get a premium off a depressed print and a fast route to cash; they do not get a market test. If you are underwriting take-privates in this vintage, the question is never the premium. It is who signed the support agreement before the premium was set.
The terms tell you what the risk is
Closing is expected in the first half of 2027 — a long runway, and deliberately so. Accelerant is an insurance business, so the gating item is state and international insurance regulatory approval rather than antitrust. The agreement carries a ticking fee of 6% per annum that accrues for a specified period if those approvals drag. Thoma Bravo has provided an equity commitment; there is no financing condition.
A ticking fee is a confession dressed as a term. It exists because both sides expect the regulatory calendar to be the binding constraint, and it prices the delay in advance rather than leaving shareholders to absorb it. Note the direction: the buyer pays more the longer it takes. That is the seller’s bankers doing their job, and it also tells you the buyer is confident enough to accept the meter running.
The 2025 IPO class keeps failing the same test
Accelerant is the third listing of its cohort to end up on the wrong side of its own offer price in these pages. SpaceX broke below its IPO price earlier this month. Jersey Mike’s went public asking less than Blackstone paid for it. The pattern is not a market judgment on any one company. It is a judgment on 2025 pricing, when sponsors pushed deals above marketed ranges into a bid that did not persist past the lockup.
Private equity is the natural clearing mechanism for that mistake, and Thoma Bravo has been the most aggressive buyer of it. The uncomfortable arithmetic for public-market investors: the fastest way to get your money back from a broken 2025 IPO is to sell the company to the kind of firm that took it public.
What to watch
- The proxy. With 82% pre-committed, the interesting disclosure is the background-of-the-merger section — when Thoma Bravo first approached, and whether anyone else was contacted.
- The spread. Trading at a discount to $20.25 tells you the market is pricing the 2027 timeline and the regulatory tail, not doubting the deal.
- Copycats. Specialty insurance and insurance-adjacent tech are now the cheapest listed assets relative to their private marks. Expect at least one more.